Discovery of a new antifungal drug to combat resistant fungal infections
Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi
This study is working on a new antifungal medicine called turbinmicin to help people with weakened immune systems who are fighting tough fungal infections, using natural ingredients from marine bacteria to find the best treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11043368 on NIH RePORTER |
What this research studies
This research focuses on developing a new antifungal drug called turbinmicin, which targets drug-resistant fungal infections, particularly those affecting immunocompromised patients. The researchers are utilizing natural products derived from marine bacteria to identify effective compounds against multidrug-resistant fungi like Candida auris. The project involves optimizing the drug's safety and efficacy through various formulations and testing methods. If successful, this research aims to provide a safe and effective treatment option for patients suffering from severe fungal infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are immunocompromised patients who are at high risk for severe fungal infections.
Not a fit: Patients with fungal infections that are not resistant to current antifungal treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, safe, and effective antifungal treatment for patients with drug-resistant fungal infections.
How similar studies have performed: Other research has shown promise in developing antifungal agents from natural products, indicating potential success for this novel approach.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Andes, David R — University of Wisconsin-Madison
- Study coordinator: Andes, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.